Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major
Status:
Unknown status
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
Thalassemia major is a genetic disorder affecting hemoglobin synthesis, rendering individuals
dependent upon lifelong blood transfusions. Consequently, iron overload occurs and patients
have shortened life expectancy with the most common cause of death being heart failure. This
trial tests whether the combination of traditional therapy (deferoxamine) with a newer drug
(deferiprone) will prove more effective in removing cardiac iron than deferoxamine alone.
Phase:
Phase 4
Details
Lead Sponsor:
Royal Brompton & Harefield NHS Foundation Trust
Collaborators:
Apotex Inc. CORDA, The Heart Charity The Cooley's Anemia Foundation, The Cooley’s Anemia Foundation, The UK Thalassemia Society